Abstract: An oral solid preparation including a base compound and a powdery or granular additive colored with a colorant and a method of manufacturing an oral solid preparation including the steps of: coloring an additive with a colorant, mixing the resultant additive with a base compound, and tableting the mixture.

Abstract: Provided is an oral preparation that contains a medicinal component having an unpleasant taste and that has better qualities, for example, generation of an analogue can be reduced, better than oral preparations that are produced by conventional techniques and that contain a medicinal component having an unpleasant taste. This objective is achieved by adding a coating agent on the medicinal component and a disintegrator that has a carboxymethyl group.

Abstract: Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.

Abstract: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.

Abstract: An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.

Abstract: A method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide bonded oxygen carrier solution across a separation membrane from an oxygen-dissolved solution; and exposing the setting part to the light and a method of removing carbon monoxide from an oxygen carrier including setting a carbon monoxide oxygen carrier solution across a hollow fiber separation membrane from an oxygen-dissolved solution; and exposing the setting part to light.

Abstract: An information processing apparatus comprising a secure information unit that is set to the state not requiring security in the case where the data is transferred from a user memory space to a general purpose register, and that is set to the state requiring security in the case where the data is transferred from a secure memory space to the general purpose register. An encryption key in the secure memory space is prevented from being stolen by prohibiting the data transfer to the user memory space from the general purpose register with the value of the secure information unit set to the state requiring security.

Abstract: The present invention provides a production method of a functional recombinant human hemoglobin, which comprises transforming a yeast of the genus Pichia with an expression vector containing a DNA encoding a human hemoglobin ?-chain (Hb?), which is under regulation of a promoter functional in a yeast of the genus Pichia, and an expression vector containing a DNA encoding a human hemoglobin ?-chain (Hb?), which is under regulation of a promoter functional in a yeast of the genus Pichia, culturing the yeast in a medium, and recovering the human hemoglobin from the obtained culture. The present invention also provides an expression vector containing AOX1 promoter, DNA encoding Hb?, terminator functional in a yeast of the genus Pichia, AOX1 promoter, DNA encoding Hb? and terminator functional in the yeast of the genus Pichia in this order from the upstream side in transcriptional direction.

Abstract: Glycosylated albumin as a drug carrier for a DDS targeting the liver (particularly kupffer's cell) can be provided by mutating a DNA encoding albumin to encode a mutant albumin containing a partial amino acid sequence permitting glycosylation modification by eukaryotic cell, preferably a consensus sequence of N-linked sugar chain, introducing an expression vector containing the mutant DNA into a host eukaryotic cell, preferably a host cell permitting addition of a high-mannose type sugar chain, culturing the obtained transformant, and recovering a glycosylated albumin protein from the obtained culture.

Abstract: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.

Abstract: A basis particle comprises a basic or acidic basis particle coated by a water-insoluble coating film, wherein the water-insoluble coating film contains a substance that is acidic with respect to the basic basis or basic with respect to the acidic basis. According to the basis particles (i.e., a main ingredient or an active drug)of the present invention, it is possible to temporarily adjust pH occurring in the immediate proximity of the basis particles by using a coating film, elution of the basis particles is suppressed and superior elution is exhibited without dependence on bodily pH. It is also possible to mask tastes such as the bitterness of the basis and it is possible to ingest drugs without sensing any bitterness.

Abstract: An oral solid preparation including a base compound and a powdery or granular additive colored with a colorant and a method of manufacturing an oral solid preparation including the steps of: coloring an additive with a colorant, mixing the resultant additive with a base compound, and tableting the mixture.

Abstract: An orally-disintegrating tablet comprises a principal agent, a sugar alcohol powder and a sugar alcohol granule, wherein the orally-disintegrating tablet has a hardness of 30 N or greater. According to the present invention, a smooth swallowing orally-disintegrating tablet, for which both the mechanical strength and the disintegration properties in the buccal cavity are favorable with using a normal tableting machine and without using special devices and the feeling on the tongue and taste are favorable, is provided.

Abstract: A pharmaceutical composition containing an artificial oxygen carrier, which has high oxygen carrying efficiency; and has a required colloid osmotic pressure, an appropriate crystalloid osmotic pressure, pH, and electrolyte balance. The composition is prepared by appropriately adding at least one substance selected from the group consisting of a compound capable of providing a colloid osmotic pressure, an electrolyte, a saccharide, an amino acid, an antioxidant, a pH adjuster, and an isotonizing agent to a preparation including a liposome-encapsulated hemoglobin in which a hemoglobin is encapsulated in a liposome or to a preparation including a conjugate of a porphyrin-iron complex and albumin.

Abstract: An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.

Abstract: Provided is a high-copy-number, high-expression vector capable of producing a protein having satisfactory functions and activity of the same level as that of a natural form of the protein, in a large quantity and in a simple manner. Also provided is a vector including: (A) a target gene or a cloning site of the target gene, (B) a sequence element necessary for the high copying of the target gene, (C) a sequence element necessary for the expression of the target gene and a methionine aminopeptidase gene; a method of producing the vector; a transformant having the vector introduced therein; and a process for producing a protein using the transformant.

Abstract: This invention provides albumin preparations with safety and without any risk of side effects, which are free from viruses or contaminating proteins and can be stably stored over a long time while showing neither changes in appearance nor decrease in content. There are provided a stabilized albumin preparation produced by uniformly mixing a medium-chain fatty acid or a salt thereof and a sulfur-containing amino acid or a derivative thereof with an aqueous albumin solution (e.g., a buffer such as phosphate buffer which can be administered as pharmaceutical preparations, injection water, or a physiological saline) and dissolving them therein, and then processing the mixture solution into a formulation suitable for parenteral administration such as an intravenous fluid preparation or an injectable solution, and a stabilization method for an albumin preparation.

Abstract: The present invention provides a method of producing a complex of albumin and a deoxy form metal complex having a porphyrin structure, which includes mixing albumin and a metal complex having a porphyrin structure under a gas atmosphere substantially free of carbon monoxide and oxygen, as a method of producing an artificial oxygen carrier containing a complex of albumin and a metal complex having a porphyrin structure, under a deoxidation (nitrogen, other inert gases) atmosphere without using carbon monoxide.

Abstract: A solid pharmaceutical preparation for dialysis which does not contain any acetic acid and a production process thereof. The solid pharmaceutical preparation for dialysis contains two pharmaceutical preparations: a solid pharmaceutical preparation (A) composed of particles having an average particle size of about 100 ?m to 1,500 ?m and containing one or more electrolytes selected from sodium chloride, calcium chloride, magnesium chloride, and potassium chloride, and an organic acid other than acetic acid and/or a salt of the organic acid; and a solid pharmaceutical preparation (B) containing sodium bicarbonate.

Abstract: The present invention relates to a solid formulation for dialysis and a method for producing the same. The formulation is a mixture of: first particles having a coating layer containing magnesium chloride and sodium acetate on surfaces of sodium chloride particles; and second particles having a coating layer containing calcium chloride and sodium acetate on the surfaces of sodium chloride particles, at least one of the coating layers of the first and second particles further including potassium chloride. In the formulation of the present invention, aggregation or consolidation between particles due to moisture absorption thereof can be suppressed. Besides, the content of each component in the formulation becomes uniform, so as to quickly dissolve in water when used. In addition, the formulation of the present invention is an extremely stable solid formulation in which decomposition of glucose hardly occurs even when a formulation containing electrolyte components and acetic acid further contains glucose.